Every material Form 8-K Hinge Health, Inc. has filed with the SEC since August 04, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Hinge Health reported third-quarter 2026 revenue of $235.0 million, up 52% from a year earlier, and GAAP diluted net income of $0.66 per share compared with a loss of $0.02 per share in Q3 2025. The company raised its full-year 2026 revenue guidance to $879 million to $881 million and disclosed that President James Pursley will step down effective January 1, 2027, and join the Board on January 4, 2027.
Q3 2026 revenue was $235.0 million, up from $154.2 million in Q3 2025; GAAP income from operations was $50.3 million versus a $6.1 million loss a year earlier.
GAAP diluted EPS was $0.66 versus a loss of $0.02; non-GAAP diluted EPS was $0.71 versus $0.32.
Full-year 2026 revenue guidance was raised to $879 million to $881 million; Q4 2026 revenue is expected at $249 million to $251 million.
Free cash flow was $112.7 million in Q3 2026, versus $81.3 million a year earlier; Daniel Perez, CEO, will also become President.
Hinge Health entered an office lease on August 18, 2026 for about 119,278 rentable square feet at 300 Mission Street in San Francisco. Estimated base rent over the term is about $86.0 million, plus operating costs, and the lease is expected to expire February 28, 2037.
Estimated base rent over the lease term is about $86.0 million, plus the company's share of operating expenses, taxes and insurance
Landlord provides a tenant improvement allowance of up to $17.9 million
Company must post a $2.8 million irrevocable standby letter of credit to secure the lease
One five-year renewal option and a one-time early termination right effective January 31, 2035, subject to conditions including a termination payment
Hinge Health reported second-quarter 2026 revenue of $212.8 million, up 53% from a year earlier, and GAAP diluted earnings of $0.52 per share, compared with a loss of $13.10 per share in the second quarter of 2025. The company raised its full-year 2026 revenue guidance to $856 million to $860 million, agreed to buy Cylinder Health for $105 million in cash, and its board increased the share repurchase program by $300.0 million, for a total authorization of $496.5 million.
Q2 2026 revenue was $212.8 million, up 53% from $139.1 million in Q2 2025; GAAP income from operations was $40.4 million, compared with a loss of $580.7 million a year earlier
Full-year 2026 revenue guidance raised to $856 million to $860 million; Q3 2026 revenue guidance set at $223 million to $225 million
Definitive agreement to acquire Cylinder Health, Inc. for $105 million in cash, expected to close in the third quarter of 2026
As of July 29, 2026, $196.5 million of stock had been repurchased under the program; the board approved a $300.0 million increase, bringing total authorization to $496.5 million
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Hinge Health, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →